Dabigatran Etexilate in Patients With Mechanical Heart Valves
A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 328 participants.
Also called NCT01452347
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 328 participants
- Sponsor
- Registry
-
NCT01452347 -
2010-022685-27
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Belgium, Canada, Czechia, Denmark, France, Germany, Netherlands, Norway, Poland, Sweden
- Registry status
- Terminated
Technical summary
Registry record NCT01452347. Randomized; no masking; primary purpose prevention. Start 2011-10 (registry gives no type); primary completion 2013-06 (actual). Results posted on 2014-08-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dabigatran Etexilate in Patients With Mechanical Heart Valves
- Acronym
- RE-ALIGN
- Condition
- Heart Valve Diseases
- Intervention (Drug)
- warfarin 1mg
- Intervention (Drug)
- dabigatran etexilate intermediate dose
- Intervention (Drug)
- dabigatran etexilate low dose
- Intervention (Drug)
- warfarin 5mg
- Intervention (Drug)
- dabigatran etexilate high dose
- Intervention (Drug)
- warfarin 3mg
- Lead sponsor
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct01452347- Content hash
cceaec6f2f867ab97cb60463202009cae62375dee3f0c8eb12eb0de1d6bb459e